Filter Results
10 results
- Data for: Quality of life analysis in lung cancer: a systematic review of phase III trials published between 2012 and 2018The Excel file includes the data used for analysis
- Dataset
- Data for: Comparing Three Different Anti-PD-L1 Antibodies for Immunohistochemical Evaluation of Small Cell Lung Cancerpatients imformation
- Dataset
- Data for: A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancerAttached data are raw data that can perform the meta analysis of this article using REVMAN software, and the extracted time to event data from Feng's study named Feng study .sav, of which we can open and run it using SPSS software.
- Dataset
- Data for: Comparison of ALK Detection by FISH, IHC and NGS to Predict Benefit from Crizotinib in Advanced Non-small-cell Lung CancerThe raw data of patients who received Crizotinib
- Dataset
- Data for: Predictive Value of a Prognostic Model Based on Pathologic Features in Lung Invasive AdenocarcinomaPredictive Value of a Prognostic Model Based on Pathologic Features in Lung Invasive Adenocarcinoma
- Dataset
- Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapySupplemental Table. Tumour responses in patients with uncommon EGFR mutations. Single mutations, G719X, S768I, L861Q; Complex mutations, G719X+S768I/+L861Q; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; P-value based on the Chi-square test.
- Dataset
- Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapySupplement 3. Major clinicopathological characteristics of 99 patients with common EGFR mutation.
- Dataset
- Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapySupplement 2. Major clinicopathological characteristics of 99 patients with uncommon EGFR mutation.
- Dataset
- Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapySupplemental figure. The effect of EGFR-TKIs in patients with uncommon EGFR mutations showed a similar PFS, but OS was lower than in advanced lung adenocarcinoma patients with common EGFR mutations.
- Dataset
- Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapySupplement 1. Major clinicopathological characteristics of 4276 cases.
- Dataset